Literature DB >> 29205263

LSD1 (KDM1A)-independent effects of the LSD1 inhibitor SP2509 in cancer cells.

Jürgen Sonnemann1,2, Miriam Zimmermann1,2, Christian Marx3, Franziska Ebert1,2, Sabine Becker1,2, Marie-Luise Lauterjung1, James F Beck1.   

Abstract

Entities:  

Keywords:  LSD1 (KDM1A); LSD1 inhibitors; LSD1 knockout; SP2509; histone lysine demethylases (KDMs)

Mesh：

Substances：

Year:  2017        PMID： 29205263     DOI： 10.1111/bjh.14983

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

1.  Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.

Authors:  Cavan P Bailey; Mary Figueroa; Achintyan Gangadharan; Yanwen Yang; Megan M Romero; Bridget A Kennis; Sridevi Yadavilli; Verlene Henry; Tiara Collier; Michelle Monje; Dean A Lee; Linghua Wang; Javad Nazarian; Vidya Gopalakrishnan; Wafik Zaky; Oren J Becher; Joya Chandra
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

2.  What potential is there for LSD1 inhibitors to reach approval for AML?

Authors:  Manu R Pandey; Eunice S Wang
Journal:  Expert Opin Emerg Drugs       Date:  2019-12       Impact factor: 4.191

3.  Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology.

Authors:  Natalia Sacilotto; Paola Dessanti; Michele M P Lufino; Alberto Ortega; Alejandra Rodríguez-Gimeno; Jordi Salas; Tamara Maes; Carlos Buesa; Cristina Mascaró; Robert Soliva
Journal:  ACS Pharmacol Transl Sci       Date:  2021-11-12

4.  Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines.

Authors:  Darcy Welch; Elliot Kahen; Brooke Fridley; Andrew S Brohl; Christopher L Cubitt; Damon R Reed
Journal:  PLoS One       Date:  2019-09-24       Impact factor: 3.240

Review 5.  LSD1/KDM1A inhibitors in clinical trials: advances and prospects.

Authors:  Yuan Fang; Guochao Liao; Bin Yu
Journal:  J Hematol Oncol       Date:  2019-12-04       Impact factor: 17.388

Review 6.  Targeting the GFI1/1B-CoREST Complex in Acute Myeloid Leukemia.

Authors:  Maaike G J M van Bergen; Bert A van der Reijden
Journal:  Front Oncol       Date:  2019-10-09       Impact factor: 6.244

Review 7.  Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials.

Authors:  Zhenyi Niu; Runsen Jin; Yan Zhang; Hecheng Li
Journal:  Signal Transduct Target Ther       Date:  2022-10-05

8.  Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations.

Authors:  Iris F Macheleidt; Priya S Dalvi; So-Young Lim; Sonja Meemboor; Lydia Meder; Olivia Käsgen; Marion Müller; Karolin Kleemann; Lingyu Wang; Peter Nürnberg; Vanessa Rüsseler; Stephan C Schäfer; Esther Mahabir; Reinhard Büttner; Margarete Odenthal
Journal:  Mol Oncol       Date:  2018-10-13       Impact factor: 6.603

Review 9.  LSD1/KDM1A, a Gate-Keeper of Cancer Stemness and a Promising Therapeutic Target.

Authors:  Panagiotis Karakaidos; John Verigos; Angeliki Magklara
Journal:  Cancers (Basel)       Date:  2019-11-20       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.